Introduction
============

Diabetes is a risk factor of coronary heart disease (CHD) which is a leading cause of mortality.[@b1] Many studies have revealed that some patients with diabetes may have asymptomatic CHD, and a retrospective study and a small randomised trial suggested a possible benefit from CHD screening.[@b2] [@b3] In a large randomised controlled trial, however, routine screening for asymptomatic CHD among patients with type 2 diabetes was of no benefit to the cardiac outcome.[@b4] In addition, traditional coronary risk factors such as hypertension and dyslipidaemia were not associated with silent ischaemia and asymptomatic CHD.[@b5] [@b6] Therefore, aggressive routine screening for asymptomatic CHD among all patients with diabetes with or without these risk factors is not recommended at present. No definite markers for effectively identifying the presence of asymptomatic CHD in patients with diabetes presently exist, and further investigations are needed.

In recent studies, microvascular and macrovascular diseases were associated with the subsequent coronary events. Diabetic retinopathy was associated with the onset of CHD and cardiovascular disease.[@b7; @b8; @b9; @b10] Patients with proliferative diabetic retinopathy (PDR) and after photocoagulation had a particularly high risk of cardiovascular disease.[@b11] An independent association was also observed between renal dysfunction and cardiovascular events,[@b12; @b13; @b14; @b15; @b16] and the risk of cardiovascular disease was increased when proteinuria developed.[@b17] [@b18] Moreover, many studies suggested that macrovascular diseases such as peripheral arterial disease (PAD) and cerebrovascular disease were strongly associated with CHD.[@b19; @b20; @b21; @b22; @b23; @b24]

Thus, we hypothesised that asymptomatic CHD may be present in many patients with type 2 diabetes with vascular complications such as advanced diabetic retinopathy, renal dysfunction, PAD or cerebrovascular disease, although each complication is regarded as aetiologically non-identical to others, especially between micro- and macrovascular complications for which hyperglycaemia and hypercholesterolaemia play an important role, respectively.[@b10] [@b24] The aim of this study was to assess the prevalence of asymptomatic CHD among patients with type 2 diabetes with vascular complications and no known CHD.

Methods
=======

Study design and participants
-----------------------------

From April 2009 to August 2010, we conducted a cross-sectional study, and patients were enrolled at the National Center for Global Health and Medicine in Tokyo, Japan. The institutional review boards approved this study, and all the patients provided their written informed consent. Eligibility criteria included patients with type 2 diabetes without suggestive symptoms of CHD between the ages of 40 and 75 years. Additionally, all the patients had one or more of the following four criteria: (1) PDR or after photocoagulation; (2) renal dysfunction; (3) PAD; and (4) cerebrovascular disease. An ophthalmologist diagnosed the PDR or after photocoagulation. Renal dysfunction was defined as an estimated glomerular filtration rate (GFR) of \<30 ml/min/1.73 m^2^ or an estimated GFR of \<45 ml/min/1.73 m^2^ plus albuminuria, corresponding to ≥30 mg/day or ≥30 mg/g of creatinine. The estimated GFR was calculated using the following formula,[@b25] as recommended by the Japanese Society of Nephrology: estimated GFR (ml/min/1.73 m^2^)=194× Cre^−1.094^× Age^−0.287^ (×0.739 if the patient is a woman). PAD was defined as an ankle--brachial index (ABI) \<0.9, confirmed peripheral artery stenosis based on radiological images, or after surgical treatment. Cerebrovascular disease was defined as stroke or transient ischaemic attack. The exclusion criteria included (1) known CHD or suspected CHD; (2) the presence of antibodies to glutamic acid decarboxylase; (3) acute kidney injury; and (4) a very poor prognosis and inappropriate conditions for testing. The inclusion criteria and exclusion criteria were confirmed using clinical records, laboratory data, questionnaires and questioning by the physician.

Diagnostic approach and evaluation of outcomes
----------------------------------------------

Stress single-photon emission computed tomography (SPECT) has a high negative predictive value to rule out CHD and does not require the use of contrast medium. To avoid unnecessary tests, we first performed stress SPECT in all the patients who met the study criteria; patients who exhibited myocardial perfusion abnormalities then underwent conventional coronary angiography (CAG), 64-slice multidetector-row computed tomography (MDCT) coronary angiography, or both examinations. We referred to the conventional CAG findings when the patients underwent both imaging procedures. The left main coronary artery, the left anterior descending coronary artery, the left circumflex coronary artery and the right coronary artery were each assessed using the American Heart Association classification.[@b26] We diagnosed asymptomatic CHD when a coronary artery with ≥50% diameter stenosis was confirmed using CAG.[@b19] The primary end point of this study was the prevalence of asymptomatic CHD among patients with type 2 diabetes with vascular complications.

Stress SPECT
------------

ECG-gated stress SPECT imaging was performed in all the patients using a dual-headed γ camera (E.cam; Siemens, Munich, Germany). Patients underwent exercise stress (n=75) according to the Bruce protocol. Exercise testing was terminated when the patients achieved a heart rate of 85% or more of the predicted maximal heart rate, a sufficient blood pressure response (such as a systolic blood pressure ≥250 mm Hg), a feeling that further exercise was impossible or significant severe ischaemic changes on an ECG recording. Patients who were unable to perform the exercise (n=47) underwent a pharmacological stress test comprised of a 6 min adenosine infusion protocol, as recommended by The Japanese Society of Nuclear Cardiology. Technetium-99m tetrofosmin SPECT imaging was performed using a 1-day protocol in 108 patients, and thallium-201 was used in 14 patients. Two experienced doctors of nuclear cardiology independently evaluated the images without knowing the details of the clinical information. We diagnosed myocardial perfusion abnormalities when one or more of the doctors pointed out the presence of abnormal myocardial perfusion on the stress SPECT images. For the image analysis, quantitative gated SPECT data were also used. Prior to interpreting the images, the data were reviewed for artefacts. A 20-segment model was used for reference, and the images were comprehensively interpreted. Ischaemia was diagnosed when one or more of the doctors pointed out a reversible defect. On the other hand, a scar was diagnosed when the defect was not reversible.

Conventional CAG
----------------

When patients had severe coronary calcifications with coronary artery calcium (CAC) scores ≥400 Agatston units, an irregular heart rhythm, advanced renal dysfunction or severe stenosis on MDCT coronary angiography, we aggressively conducted conventional CAG to assess the coronary arteries. Conventional CAG images were interpreted by two experienced cardiologists blinded to the detailed patient characteristics in a usual clinical setting.

Sixty-four-slice MDCT
---------------------

In the absence of contraindications, the patients who had myocardial perfusion abnormalities underwent MDCT tests to determine their CAC scores followed by CAG. The imaging was performed using 64-slice MDCT with a slice thickness of 0.5 mm (Aquilion64; Toshiba Medical Systems, Otawara, Japan). If necessary and tolerated, oral beta-blockers (metoprolol 40--100 mg) were provided before the scan to achieve a heart rate \<60 beats/min. We performed a non-enhanced prospective electrocardiographically gated scan to measure the CAC scores, which were calculated using the Agatston method.[@b27] The MDCT coronary angiography was performed using 64×0.5 mm collimation and retrospective electrocardiographic gating. MDCT images were interpreted by an experienced cardiologist in cooperation with radiologists who were unaware of the detailed clinical backgrounds in a usual clinical setting. All the coronary arteries and side branches with a luminal diameter ≥ 2.0 mm were assessed.

Other measurements
------------------

The rest and exercise stress ECG tests were assessed by a trained cardiologist who had no knowledge of the clinical findings of the patients. We diagnosed an abnormality on the rest ECG findings if ST segment abnormalities, T wave abnormalities, an abnormal Q wave, or a complete left bundle branch block were observed; ischaemia was diagnosed on an exercise stress ECG if the exercise induced any ischaemic changes.

We measured the ABI to evaluate PAD and the brachial--ankle pulse wave velocity to assess the presence of arteriosclerosis in the peripheral arteries (Form PWV/ABI; Colin Company, Komaki, Japan).[@b28] The lowest ABI and the highest brachial--ankle pulse wave velocity for the left and right sides were used in subsequent analyses.

To estimate cardiac function such as the ejection fraction and the wall motion, we conducted an echocardiography examination (Aplio 80; Toshiba Medical Systems, Otawara, Japan). The examinations were performed by a trained ultrasonographer and cardiologist who had no knowledge of the patients\' clinical information. Doppler echocardiography was also performed to assess the peak Doppler velocities of the early (E) and late diastolic flows (A), the deceleration time (DT) and the E/A ratio for the mitral inflow. Moreover, tissue Doppler imaging of the mitral annulus was measured from the apical four-chamber view. A sample volume was placed at the septal mitral annulus, and the early (E′) diastolic velocity was measured. We analysed the E/E′ ratio to assess the cardiac function.[@b29]

The carotid intima-media thickness (IMT) was evaluated using high-resolution B-mode ultrasound with a 10 MHz linear transducer (Aplio XG; Toshiba Medical Systems, Otawara, Japan).[@b30] A trained ultrasonographer and a doctor or a skilled doctor alone who were unaware of the patient\' characteristics assessed the maximum carotid IMT. The maximum carotid IMT was defined as the thickest IMT for the left and right sides from the common carotid artery to the internal carotid artery.

Statistical methods
-------------------

Data are presented as the number (%), mean with SD, and median with lower and upper ends of the IQR. Continuous variables were compared using t tests and Wilcoxon rank sum tests. Categorical variables were compared using χ^2^ tests. A multivariate logistic-regression analysis of coronary risk factors, such as age, sex, overweight or obesity, current smoking habit, hypertension and dyslipidaemia, was performed to identify coronary risk factors associated with asymptomatic CHD. p values \<0.05 according to a two-sided test were considered statistically significant for all the tests. All analyses were performed using Stata software, V.11.1.

Results
=======

A total of 1008 patients with type 2 diabetes between the ages of 40 and 75 years were screened, and 219 met the inclusion criteria for this study. Of the 206 eligible patients without any exclusion criteria, 122 consented to participate ([figure 1](#fig1){ref-type="fig"}). The clinical characteristics of this study population are presented in [table 1](#tbl1){ref-type="table"}. The mean age was 64.1±8.3 years, 84 (68%) were men, and the mean A1C was 7.7±1.5%. The numbers of patients with PDR or after photocoagulation, renal dysfunction, PAD and cerebrovascular disease were 76 (62%), 25 (20%), 21 (17%) and 46 (37%), respectively.
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###### 

Characteristics of study population[\*](#table-fn1){ref-type="table-fn"}

                                                                               N     All                     Men                      Women
  ---------------------------------------------------------------------------- ----- ----------------------- ------------------------ --------------------
  Age (years)                                                                  122   64.1 (8.3)              63.9 (8.3)               64.6 (8.5)
  Weight (kg)                                                                  122   64.6 (12.4)             66.7 (12.1)              60.1 (12.2)
  Body-mass index (kg/m^2^)[†](#table-fn2){ref-type="table-fn"}                122   24.5 (4.0)              24.3 (3.7)               25.1 (4.5)
  Waist (cm)                                                                   112   90.3 (11.2)             89.8 (10.7)              91.5 (12.5)
  Smoking                                                                      122                                                    
   Non                                                                               47 (39%)                16 (18%)                 31 (82%)
   Former                                                                            37 (30%)                34 (41%)                 3 (8%)
   Current                                                                           38 (31%)                34 (41%)                 4 (10%)
  History of cerebrovascular disease[‡](#table-fn3){ref-type="table-fn"}       122   46 (37%)                32 (38%)                 14 (36%)
  Duration of diabetes (years)                                                 122   16.0 (10.2)             16.5 (9.8)               15.2 (11.1)
  Age (years) at the time of diabetes diagnosis                                122   49.0 (12.2)             48.4 (11.8)              50.4 (13.1)
  Any diabetic retinopathy                                                     122   97 (79%)                67 (79%)                 30 (79%)
  Proliferative diabetic retinopathy or after photocoagulation                 122   76 (62%)                50 (59%)                 26 (68%)
  A1C (%)                                                                      122   7.7 (1.5)               7.8 (1.7)                7.5 (1.2)
  Treatment for diabetes                                                       122                                                    
   Diet                                                                              7 (6%)                  7 (8%)                   0 (0%)
   Oral agents                                                                       59 (48%)                37 (44%)                 22 (58%)
   Insulin                                                                           15 (12%)                13 (16%)                 2 (5%)
   Insulin+oral agents[§](#table-fn4){ref-type="table-fn"}                           41 (34%)                21 (32%)                 14 (37%)
  Hypertension[¶](#table-fn5){ref-type="table-fn"}                             122   95 (77%)                66 (78%)                 29 (76%)
   Treatment                                                                                                                          
   Angiotensin II receptor blockers/angiotensin-converting enzyme inhibitors         88 (72%)                61 (72%)                 27 (71%)
   Calcium-channel blockers                                                          55 (45%)                37 (44%)                 18 (47%)
   Diuretics                                                                         16 (13%)                9 (10%)                  7 (18%)
   Others                                                                            4 (3%)                  3 (3%)                   1 (2%)
  Dyslipidaemia[\*\*](#table-fn6){ref-type="table-fn"}                         122   90 (73%)                60 (71%)                 30 (79%)
   Total cholesterol (mg/dl)                                                         192.7 (39.0)            194.7 (42.4)             188.3 (30.9)
   LDL cholesterol (mg/dl)                                                           115.6 (40.5)            119.6 (43.8)             106.5 (30.4)
   HDL cholesterol (mg/dl)                                                           52.4 (14.8)             51.1 (13.5)              55.3 (17.2)
   Triglyceride (mg/dl)                                                              143.3 (85.9)            142.7 (86.1)             144.6 (86.7)
   LDL/HDL ratio                                                                     2.4 (1.1)               2.5 (1.1)                2.2 (0.9)
  Treatment                                                                                                                           
   Statin                                                                            47 (38%)                25 (29%)                 22 (57%)
   Others                                                                            9 (7%)                  7 (8%)                   2 (5%)
  Use of aspirin                                                               122   33 (27%)                23 (27%)                 10 (26%)
  Creatinine (mg/dl)                                                           120   1.04 (0.60)             1.08 (0.60)              0.94 (0.60)
  Estimated glomerular filtration rate (ml/min/1.73 m^2^)                      120   62.1 (22.0)             63.3 (20.4)              59.7 (25.4)
   \<45                                                                              28 (23%)                17 (20%)                 11 (28%)
   \<30                                                                              10 (8%)                 5 (6%)                   5 (13%)
  Use of haemodialysis                                                         2     2 (1%)                  2 (2%)                   0 (0%)
  Albuminuria (mg/day or mg/g of creatinine)                                   117                                                    
   \<30                                                                              32 (27%)                16 (20%)                 16 (45%)
   30--299                                                                           40 (34%)                28 (34%)                 12 (33%)
   ≥300                                                                              45 (39%)                37 (46%)                 8 (22%)
  Renal dysfunction[††](#table-fn7){ref-type="table-fn"}                       122   25 (20%)                17 (20%)                 8 (21%)
  Brain natriuretic peptide (pg/ml)                                            113   37.2 (26.1 to 48.2)     19.4 (7.5 to 47.5)       24.8 (11 to 39.8)
  Rest ECG                                                                                                                            
   Any abnormal findings                                                       122   27 (22%)                19 (22%)                 8 (21%)
   Abnormal Q wave changes                                                           3 (2%)                  2 (2%)                   1 (2%)
  Ischaemic findings on exercise stress ECG                                    64    25 (39%)                15 (36%)                 10 (43%)
  Cardiothoracic ratio on chest x-ray (%)                                      113   48.0 (4.4)              47.6 (4.5)               48.9 (4.0)
  Ankle--brachial index                                                        122   1.07 (0.17)             1.06 (0.18)              1.09 (0.17)
  Brachial--ankle pulse wave velocity (cm/s)                                   108   2012.2 (377.3)          1940.5 (300.3)           2168.3 (474.8)
  Peripheral arterial disease                                                  122   21 (17%)                17 (20%)                 4 (10%)
  Echocardiography[‡‡](#table-fn8){ref-type="table-fn"}                                                                               
   Ejection fraction (%)                                                       108   67.3 (8.6)              66.4 (9.5)               69.4 (6.0)
   Septal+posterior wall thickness (mm)                                        108   21.2 (3.4)              21.3 (3.4)               20.9 (3.4)
   \>25                                                                              10 (9%)                 6 (8%)                   4 (11%)
   E/A ratio                                                                   107   0.76 (0.21)             0.77 (0.17)              0.75 (0.28)
   Deceleration time (ms)                                                      107   236.4 (59.1)            232.6 (60.5)             244.6 (56.0)
   E/E′ ratio                                                                  96    11.3 (3.4)              11.0 (2.86)              12.1 (4.35)
   Abnormal wall motion                                                        108   6 (5%)                  6 (8%)                   0 (0%)
  Ultrasound of carotid artery                                                 81                                                     
   Maximum carotid intima-media thickness (mm)                                       1.78 (1.07)             1.97 (1.13)              1.39 (0.86)
   ≥1.1                                                                              53 (67%)                41 (77%)                 12 (46%)
  Coronary artery calcium scores (Agatston units)                              83    216.8 (52.0 to 602.7)   300.4 (65.6 to 1201.2)   110.9 (0 to 275.8)

To convert the values for cholesterol and triglycerides to millimoles per litre (mmol/l), multiply by 0.02586 and 0.01129, respectively.

Data are number, number (%), mean (SD) or median (IQR).

Body-mass index was calculated as the weight in kilograms divided by the square of height in metres.

Cerebrovascular disease was defined as stroke or transient ischaemic attack.

Oral agents for the treatment of diabetes included metformin, sulfonylureas, thiazolidinediones, meglitinides and alpha-glucosidase inhibitors.

Hypertension was defined as a systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or the use of antihypertensive medication.

Dyslipidaemia was defined as low-density lipoprotein (LDL) ≥140 mg/dl, high-density lipoprotein (HDL) \<40 mg/dl, or the use of lipid-lowering drug.

Renal dysfunction was defined as the estimated glomerular filtration rate \<30 ml/min/1.73 m^2^ or the estimated glomerular filtration rate \<45 ml/min/1.73 m^2^ plus albuminuria, which was ≥30 mg/day or ≥30 mg/g of creatinine.

E/A ratio was the ratio of the peak Doppler velocities of early to late diastolic flow in the mitral inflow. E/E′ ratio was the ratio of the peak Doppler velocities of early in the mitral inflow to the early diastolic velocity at the septal mitral annulus.

Of the 122 patients, 96 (79%) had myocardial perfusion abnormalities on stress SPECT: 70 (58%) had ischaemia and 26 (21%) had a scar. Of the 96 patients with myocardial perfusion abnormalities, 42 underwent conventional CAG, 83 underwent MDCT coronary angiography, and 39 underwent both examinations. Ten patients did not undergo either MDCT coronary angiography or CAG, and were excluded from the analysis to determine the prevalence of asymptomatic CHD. Of the 112 patients who completed the study protocol, 59 (53%) had asymptomatic CHD ([figure 2A](#fig2){ref-type="fig"}). Thus, more than half of the patients who met any one of the four inclusion criteria for vascular complications had asymptomatic CHD ([figure 2B](#fig2){ref-type="fig"}). The prevalences of asymptomatic CHD among the patients who met only one criteria and among the patients who met more than one of the four inclusion criteria for vascular complications were not significantly different (p=0.50). The prevalence of asymptomatic CHD in patients with myocardial perfusion abnormalities on stress SPECT is shown in [figure 2C](#fig2){ref-type="fig"}. The prevalences of asymptomatic CHD among patients with ischaemia and among those with a scar were not significantly different. The CAC scores for the patients with and for those without asymptomatic CHD were significantly different ([figure 2D](#fig2){ref-type="fig"}).

![Prevalence of myocardial perfusion abnormalities and asymptomatic coronary heart disease (CHD) (A). Prevalence of asymptomatic CHD for each of the vascular complications (B). Prevalence of asymptomatic CHD in patients with ischaemia or scar (C). Coronary artery calcium (CAC) scores in patients with or without asymptomatic CHD (D). PAD, peripheral arterial disease; PDR, proliferative diabetic retinopathy.](bmjopen-2011-000139fig2){#fig2}

The majority of patients with asymptomatic CHD had multivessel disease. Fifty-nine patients with asymptomatic CHD had 1.8±0.8 vessels with ≥50% diameter stenosis: 24 (41%) patients had one-vessel disease, 22 (37%) had two-vessel disease, and 13 (22%) had three-vessel disease or left main disease. The maximum percentage diameter stenosis in patients with asymptomatic CHD is also assessed. Forty-two (71%) patients had ≥75% diameter stenosis, and 24 (41%) had ≥90% diameter stenosis. The analyses of the clinical variables among the patients with and those without asymptomatic CHD are shown in [table 2](#tbl2){ref-type="table"}. Men, a current smoking habit, age at the time of diabetes diagnosis, the ejection fraction, the E/A ratio, the maximum carotid IMT and the CAC scores differed significantly between the two groups in a univariate analysis. However, abnormal findings on the rest ECG, ischaemic findings on the exercise stress ECG and abnormal wall motion on echocardiography were not significantly different. When a multivariate logistic-regression analysis was performed to identify coronary risk factors independently associated with asymptomatic CHD, the only significant predictor was male sex (OR 6.18; 95% CI 2.30 to 16.64; p\<0.001). The result was similar when the duration of diabetes was added to the multivariate analysis.

###### 

Analyses of clinical variables for asymptomatic coronary heart disease

  Univariate analysis                                                                                            
  -------------------------------------------------------------- ------------------------ ---------------------- ---------
                                                                 59 (53%)                 53 (47%)               
  Men                                                            51 (86%)                 26 (49%)               \<0.001
  Age (years)                                                    62.4 (8.8)               65.3 (7.7)             0.07
  Weight (kg)                                                    65.3 (12.9)              64.7 (12.7)            0.79
  Body-mass index (kg/m^2^)                                      24.0 (3.4)               25.3 (4.6)             0.08
  Waist (cm)                                                     90.0 (11.4)              91.1 (11.9)            0.60
  Current smoker                                                 26 (44%)                 10 (18%)               0.004
  History of cerebrovascular disease                             22 (37%)                 21 (39%)               0.80
  Duration of diabetes (years)                                   16.7 (10.5)              14.9 (10.0)            0.34
  Age (years) at the time of diabetes diagnosis                  46.7 (12.2)              51.4 (11.9)            0.04
  Any diabetic retinopathy                                       46 (78%)                 42 (79%)               0.86
  Proliferative diabetic retinopathy or after photocoagulation   36 (61%)                 34 (64%)               0.73
  A1C (%)                                                        7.3 (1.5)                7.4 (1.6)              0.76
  Use of insulin                                                 33 (55%)                 21 (39%)               0.08
  Hypertension                                                   46 (78%)                 40 (75%)               0.75
  Dyslipidaemia                                                  45 (76%)                 39 (73%)               0.74
   Total cholesterol (mg/dl)                                     192.8 (38.4)             196.0 (39.5)           0.67
   Low-density lipoprotein cholesterol (mg/dl)                   113.0 (36.6)             120.0 (38.5)           0.33
   High-density lipoprotein cholesterol (mg/dl)                  50.7 (13.7)              53.5 (15.7)            0.32
   Triglyceride (mg/dl)                                          151.5 (89.0)             136.6 (82.3)           0.36
   Low-density lipoprotein/high-density lipoprotein ratio        2.4 (1.0)                2.4 (1.0)              0.85
  Use of statin                                                  21 (35%)                 22 (41%)               0.52
  Use of aspirin                                                 16 (27%)                 15 (28%)               0.88
  Creatinine (mg/dl)                                             1.03 (0.60)              0.87 (0.35)            0.09
  Glomerular filtration rate (ml/min/1.73 m^2^)                  63.9 (20.7)              65.2 (20.0)            0.74
   \<45                                                          13 (22%)                 9 (17%)                0.50
   \<30                                                          2 (3%)                   3 (5%)                 0.56
  Albuminuria ≥30 (mg/day or mg/g of creatinine)                 43 (76%)                 32 (62%)               0.11
  Brain natriuretic peptide (pg/ml)                              20.7 (7.6 to 35.4)       17.4 (9.5 to 42.9)     0.99
  Rest ECG                                                                                                       
  Ischaemic findings on exercise stress ECG                      12 (41%)                 10 (35%)               0.66
  Cardio thoracic ratio on chest x-ray (%)                       47.3 (4.4)               48.8 (4.1)             0.08
  Ankle--brachial index                                          1.06 (0.20)              1.06 (0.15)            0.98
  Brachial--ankle pulse wave velocity (cm/s)                     1955.3 (306.4)           2067.4 (448.7)         0.14
  Peripheral arterial disease                                    12 (22%)                 8 (16%)                0.42
  Echocardiography                                                                                               
  Ejection fraction (%)                                          65.6 (9.1)               69.0 (8.0)             0.04
  Septal wall+posterior wall thickness (mm)                      20.8 (3.7)               21.2 (3.0)             0.55
   E/A ratio                                                     0.81 (0.16)              0.71 (0.24)            0.02
   Deceleration time (ms)                                        225.7 (58.2)             247.5 (61.9)           0.07
   E/E′ ratio                                                    10.8 (3.3)               11.8 (3.2)             0.15
   Abnormal wall motion                                          4 (7%)                   2 (4%)                 0.47
  Ultrasound of carotid artery                                                                                   
  Maximum carotid intima-media thickness (mm)                    2.11 (1.30)              1.41 (0.70)            0.005
   ≥1.1                                                          28 (75%)                 20 (55%)               0.07
  Coronary artery calcium scores (Agatston units)                349.8 (99.6 to 1229.1)   133.2 (0.0 to 359.0)   0.003

  Multivariate analysis                          
  ----------------------- ---------------------- ---------
  Men                     6.18 (2.30 to 16.64)   \<0.001
  Age (years)             0.94 (0.89 to 1.00)    0.07
  Body-mass index ≥25     0.49 (0.20 to 1.23)    0.13
  Current smoking         2.05 (0.75 to 5.54)    0.15
  Hypertension            1.26 (0.45 to 3.50)    0.65
  Dyslipidaemia           2.16 (0.77 to 6.05)    0.14

Data are number (%), mean (SD), median (IQR), OR, or 95% CI. To convert the values for cholesterol and triglycerides to millimoles per litre (mmol/l), multiply by 0.02586 and 0.01129, respectively.

Discussion
==========

This study reports that many patients with type 2 diabetes with vascular complications have asymptomatic CHD with multivessel disease and severe stenosis in addition to myocardial ischaemia on stress SPECT. Moreover, asymptomatic CHD was detected in more than half of the patients who met any one of the four inclusion criteria for vascular complications. The association found between asymptomatic CHD and PAD in patients with type 2 diabetes was similar to the association discovered in the previous study in which myocardial scintigraphy and CAG were used to examine patients with diabetes for the presence of silent coronary stenosis.[@b20] Many past studies have reported that some patients with diabetes have asymptomatic CHD. However, the conditions under which the patients with diabetes were most likely to have asymptomatic CHD was unclear. We demonstrated that patients with type 2 diabetes with advanced microvascular or macrovascular diseases had a far greater prevalence of myocardial perfusion abnormalities and asymptomatic CHDs, compared with previous data.[@b5] [@b6] Because the diabetic complications had progressed, the patients might have had severe autonomic denervation of the heart, accounting for their asymptomatic presentation.[@b31] The statistical analysis revealed that asymptomatic CHD was more common among men than among women. However, other coronary risk factors were not associated with asymptomatic CHD. These results may be similar to those of previous studies.[@b5] [@b6] Thus, traditional coronary risk factors might not be effective in screening for asymptomatic CHD among patients with type 2 diabetes. We could not fully examine the CAC score (n=83) and the maximum IMT (n=81) in 122 patients. However, the results of the supplemental analyses showed that both the CAC score and maximum carotid IMT were significant predictors when each factor was separately included in the multivariate analysis (CAC scores and maximum carotid IMT values for the analyses were available for 83 subjects and 75 subjects, respectively, and the p value was 0.034 and 0.036, respectively). Further research will be required to identify possibly useful markers such as the ejection fraction, E/A ratio, maximum carotid IMT and CAC scores.

Importantly, some patients without significant coronary stenosis exhibited abnormal findings, such as ischaemia on stress ECG, abnormal wall motion on echocardiography or myocardial perfusion abnormalities on stress SPECT. Although these facts might suggest the possibility of false-positive results, coronary microvascular dysfunction may be responsible for cardiac disorders because the patients had many coronary microvascular risk factors, such as diabetes, cigarette smoking, dyslipidaemia and hypertension.[@b32] [@b33] Further investigation is needed for coronary microvascular dysfunction.

Our study had several limitations. First, this study was performed at a single centre and was limited to a specific geographical area. Thus, large-scale studies at multiple centres throughout the world will be necessary to confirm these results. However, we believe that this is an extremely important study that may lead to numerous future trials and that may have a large influence on diabetic management. Second, we did not perform further tests in patients with normal myocardial perfusion on stress SPECT. Therefore, some patients with normal myocardial perfusion might have had asymptomatic CHD. However, stress SPECT has a very high sensitivity for CHD and affects the decisions regarding future treatment.[@b34] Consequently, this diagnostic approach may enable unnecessary angiography to be effectively avoided. Third, the coronary arteries in some of the patients were evaluated using MDCT coronary angiography alone. In large-scale studies, a high rate of agreement between MDCT coronary angiography and conventional CAG has been confirmed.[@b35] Furthermore, conventional CAG was performed in most of the severe calcification cases with CAC scores ≥400 Agatston units, which could be problematic for MDCT coronary angiography.[@b36] The median CAC scores in the 44 patients who underwent MDCT coronary angiography alone was 149.0 (14.1--383.4) Agatston units. Thus, we assumed that the diagnosis of CHD was accurate. Fourth, our approach based on image information representing anatomical rather than functional aspects possibly misses some of the ischaemic changes of CHD, and this may explain the lack between vasculopathy and asymptomatic CHD observed in our current survey. Lastly, we had only 21 subjects with PAD, and that may be because of the relatively low prevalence of isolated PAD (eg, PAD without CHD) in the Japanese population, and in fact a paper from Japan reported that around half of the patients with PAD in their study also had CHD.[@b37] The high mean PWV values possibly reflected advanced arteriosclerosis of the subjects. In addition, it should be mentioned that the renal function did not worsen in any of the patients after CAG and MDCT in this series of observations.

In conclusion, this study revealed that asymptomatic CHD with myocardial perfusion abnormalities was detected in more than half of the patients with type 2 diabetes with vascular complications. A relationship between CHD and sudden cardiac death has been revealed,[@b38] and we expect that the results of this study may contribute greatly to reducing myocardial infarction and sudden cardiac death among patients with type 2 diabetes. However, the best approach to treating asymptomatic CHD remains unknown. Therefore, randomised controlled trials are needed to determine the optimal management.
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